FDA clears Amgen’s Prolia for glucocorticoid osteoporosis
US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.
Read More
Tag: GIOP
Amgen’s Prolia shows promise in glucocorticoid osteoporosis
Top-line data from a late-stage trial of Amgen’s Prolia in osteoporosis patients receiving glucocorticoid therapy show that all primary and secondary targets being investigated were met.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
